Oncothyreon Announces First Patient Dosed in Randomized Phase 2 ONT-380 Combination Trial in Patients with HER2-Positive Breast Cancer
February 29, 2016 08:00 ET
|
Cascadian Therapeutics, Inc.
--Study to Evaluate ONT-380 in Combination with Herceptin and Xeloda-- --Study Will Enroll HER2-Positive Breast Cancer Patients With and Without Brain Metastases-- SEATTLE, Feb. 29, 2016 (GLOBE...
Oncothyreon Appoints Christopher Henney, Ph.D., D.Sc. as Interim CEO and Expands Board With Additions of Mark Lampert and Gwen Fyfe, M.D.
January 11, 2016 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Jan. 11, 2016 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...
Oncothyreon Announces Data for ONT-380 in HER2-Positive Breast Cancer Patients With and Without Brain Metastases at the San Antonio Breast Cancer Symposium
December 08, 2015 16:05 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 08, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...
Oncothyreon Announces Webcast to Review Updated Clinical Data on ONT-380 in HER2-Positive Breast Cancer Patients
December 02, 2015 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Dec. 02, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of therapeutic products that can improve the...
Oncothyreon to Present Updated Data on ONT-380 for the Treatment of HER2-Positive Breast Cancer at the San Antonio Breast Cancer Symposium
November 16, 2015 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 16, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY), a clinical-stage biopharmaceutical company dedicated to the development of oncology products that can improve the lives...
Oncothyreon Reports Third Quarter 2015 Financial Results
November 05, 2015 16:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Nov. 05, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY) today reported financial results for the third quarter ended September 30, 2015. Net loss for the three months ended...
Oncothyreon Announces Third Quarter 2015 Financial Results Conference Call
October 29, 2015 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Oct. 29, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, November 5, 2015 at 4:30 p.m. Eastern Time (1:30 p.m....
Oncothyreon to Present at Rodman & Renshaw Annual Global Investment Conference
September 02, 2015 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Sept. 2, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) announced today that Robert Kirkman, M.D., President and Chief Executive Officer, is scheduled to present at the Rodman &...
Oncothyreon Reports Second Quarter 2015 Financial Results
August 06, 2015 16:01 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, Aug. 6, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (NASDAQ:ONTY) today reported financial results for the second quarter ended June 30, 2015.
Net loss for the three months ended June 30,...
Oncothyreon Announces Second Quarter 2015 Financial Results Conference Call
July 30, 2015 08:00 ET
|
Cascadian Therapeutics, Inc.
SEATTLE, July 30, 2015 (GLOBE NEWSWIRE) -- Oncothyreon Inc. (Nasdaq:ONTY) today announced that it will conduct a conference call on Thursday, August 6, 2015 at 4:30 p.m. Eastern Time (1:30 p.m....